text.skipToContent text.skipToNavigation

Maximum quantity allowed is 999

Please select the quantity

CAS RN: 38821-49-7 | Product Number: C2450

Carbidopa Monohydrate


Purity: >98.0%(T)(HPLC)
Synonyms:
  • (S)-3-(3,4-Dihydroxyphenyl)-2-hydrazino-2-methylpropionic Acid Monohydrate
Product Documents:
100MG
€28.00
1   3  
1G
€178.00
1   ≥100 

*Stock available in Belgium will be delivered in 1 to 3 days
*Stock available in Japan will be delivered in 1 to 2 weeks (excludes regulated items and dry ice shipments).


Product Number C2450
Purity / Analysis Method >98.0%(T)(HPLC)
Molecular Formula / Molecular Weight C__1__0H__1__4N__2O__4·H__2O = 244.25 
Physical State (20 deg.C) Solid
Storage Temperature Room Temperature (Recommended in a cool and dark place, <15°C)
Store Under Inert Gas Store under inert gas
Condition to Avoid Air Sensitive
CAS RN 38821-49-7
Related CAS RN 28860-95-9
Reaxys Registry Number 4189448
PubChem Substance ID 125307806
SDBS (AIST Spectral DB) 52879
MDL Number

MFCD00889211

Specifications
Appearance White to Light yellow powder to crystaline
Purity(HPLC) min. 98.0 area%
Purity(Nonaqueous Titration) min. 98.0 %(calcd.on dried substance)
Specific rotation [a]20/D -21.0 ~ -23.5 deg(C=1, AlCl3 sol.)
Drying loss 5.9 to 8.8 %
Properties (reference)
Specific Rotation -22° (C=1,AlCl3 sol.)
GHS
Related Laws:
RTECS# MW5300000
Transport Information:
HS Number 2928009090
Application
Carbidopa: A Competitive Inhibitor of Aromatic L-Amino Acid Decarboxylase

Carbidopa is a competitive inhibitor of aromatic L-amino acid decarboxylase. Carbidopa is often used with L-DOPA [D0600] for the treatment of Parkinson's disease. L-DOPA, the metabolic precursor of dopamine [A0305], does cross the blood-brain barrier, and presumably is converted to dopamine in the brain. However, when L-DOPA is administered orally, it is rapidly decarboxylated to dopamine in extracerebral tissues. Administration of dopamine alone is ineffective in the treatment of Parkinson's disease apparently because dopamine does not cross the blood-brain barrier. Carbidopa inhibits decarboxylation of L-DOPA. Since its decarboxylase inhibiting activity is limited to extracerebral tissues, administration of carbidopa with levodopa makes more L-DOPA available for transport to the brain. Carbidopa does not cross the blood-brain barrier and does not affect the metabolism of L-DOPA within the central nervous system. (The product is for research purpose only.)

References


PubMed Literature


Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.

The requested SDS is not available.

Please Contact Us for more information.

Specifications
C of A & Other Certificates
Please enter Lot Number Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.

The product with the lot number searched for has been discontinued and no related documentation is available.

Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.

A sample C of A for this product is not available at this time.

Analytical Charts
Please enter Lot Number Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.

The requested analytical chart is not available. Sorry for the inconvenience.

The product with the lot number searched for has been discontinued and no related documentation is available.

Other Documents

Session Status
Your session will timeout in 10 minutes. You will be redirected to the HOME page after session timeout. Please click the button to continue session from the same page. minute. You will be redirected to the HOME page after session timeout. Please click the button to continue session from the same page.

Your session has timed out. You will be redirected to the HOME page.